tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Nick Abbott, 5 are a HOLD (62.5%), 3 are a BUY (37.5%).
Analyst Nick Abbott, currently employed carries an average stock price target met ratio of 47.22% that have a potential upside of 35.01% achieved within 200 days.
Nick Abbott’s has documented 17 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on IOVA, Iovance Biotherapeutics at 30-May-2023.
Analyst best performing recommendations are on MRNA (MODERNA).
The best stock recommendation documented was for MRNA (MODERNA) at 8/13/2021. The price target of $145 was fulfilled within 185 days with a profit of $244.78 (62.8%) receiving and performance score of 3.39.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$111
$74 (200.00%)
$125
12 days ago
(08-Nov-2024)
8/12 (66.67%)
$63.02 (131.35%)
74
5.81
Sell
$59
$22 (59.46%)
$70
16 days ago
(04-Nov-2024)
6/7 (85.71%)
$3.83 (6.94%)
51
4.71
Buy
$108
$71 (191.89%)
$151
27 days ago
(24-Oct-2024)
2/6 (33.33%)
$55.2 (104.55%)
106
3.58
Hold
$55
$18 (48.65%)
$65
1 months 5 days ago
(15-Oct-2024)
21/26 (80.77%)
$-2.31 (-4.03%)
101
7.91
Hold
$75
$38 (102.70%)
$75
2 months 1 days ago
(19-Sep-2024)
5/12 (41.67%)
$6.98 (10.26%)
83
1.58
What Year was the first public recommendation made by Nick Abbott?
